Company intelligence / Profile preview
Lykos Therapeutics
San Jose, California, United Stateslykospbc.com ↗
- Ownership
- Private
- Development stage
- NDA
01
Overview
Lykos Therapeutics has completed Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD with positive results. The trials showed PTSD remission rates of 67-71% with MDMA-assisted psychotherapy versus 32-48% with placebo-assisted therapy. The company submitted a New Drug Application (NDA) to the FDA in December 2023, with results published in Nature Medicine. As of August 2024, the FDA has made a decision requiring resubmission of the application, prompting a company reorganization.
- Therapeutic areas
- Psychiatry
- Modalities
- Psychedelic-assisted therapyMDMA-assisted therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Lykos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lykos Therapeutics.